's () Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs.
''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our own manufacturing and a really strong IP position and we've just finished some more clinical trials so it's really going well''.
4D has active clinical programmes in areas including oncology and asthma as well as COVID-19 in which they're due to start a Phase II trial shortly.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE